1. Scrip
  2. >>Scrip Asks

Scrip Asks...What Does 2022 Hold For Biopharma? Part 1: Markets, Competition And Business Strategy

Transformative AI Needed To Offset Pressures On Production, Pricing And Supply Chains

 
• By Eleanor Malone

Biopharma industry leaders highlight key concerns and opportunities across production, supply chain and commercial operations. Business transformation is top of mind for many, perhaps unsurprisingly following two years of rapid and mostly successful adaptation to the strictures of the COVID-19 pandemic.

Scrip Asks, Part 1
• Source: Alamy

As we enter the third year of the COVID-19 pandemic, the pharma industry has begun to adapt and grow around its constraints and opportunities. After the all-hands-on-deck scramble in early 2020, businesses are increasingly able to reroute their energies to other priorities once again. Nevertheless, COVID-19 has shed light on systemic weaknesses that need to be addressed, and accelerated shifts towards virtual models of working.

In terms of growth, COVID-19 therapeutics and vaccines will provide a boost in revenues over the coming years, but industry...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Scrip Asks

Scrip Asks... What Does 2025 Hold For Biopharma? Part 6: Therapeutic Area Advances

 
• By Eleanor Malone

Over 140 biopharma leaders share their views on developments to watch for in key therapeutic areas this year. Advances in multiple scientific fields are opening up new avenues for treatment.

Scrip Asks... What Does 2025 Hold For Biopharma? Part 5: Clinical Trials Trends

 
• By Eleanor Malone

A revolution is underway. Technology offers the possibility to transform multiple aspects of the traditional gold standard of drug development: the randomized controlled trial. Sharing their insights with Scrip, 30 thought leaders consider how the clinical trial landscape will evolve in 2025.

Scrip Asks... What Does 2025 Hold For Biopharma? Part 4: Artificial Intelligence and Data Science

 
• By Eleanor Malone

More than 50 executives across industry share their expectations for the impact of AI on the biopharma industry over the coming year. While target identification and drug discovery featured highly, the opportunities to engage with patients and healthcare providers more effectively and the need for suitable regulatory frameworks were also flagged up.

Scrip Asks… What Does 2025 Hold For Biopharma? Part 3: Impacts Of Political Change In US And Beyond

 
• By Eleanor Malone

What do industry leaders anticipate as the US installs president Trump once again? Beyond the biopharma sector's biggest market, geopolitical instability has increased elsewhere: how might this affect markets and companies?

More from Scrip

Stock Watch: On Q1 Vaccine Sales And Measles Outbreaks

 
• By Andy Smith

A recent study suggested that measles could become endemic in the US due to low vaccination rates. However, first-quarter vaccine sales offered a more nuanced picture.

Merck & Co.’s RSV Antibody Approved In US In Time To Compete With Blockbuster Beyfortus

 
• By Mandy Jackson

The US FDA approved Merck’s Enflonsia (clesrovimab) to prevent RSV in newborns and infants on the same day Sanofi assured that it would ship Beyfortus in time for the 2025-2026 RSV season.

Metsera’s Amylin Analog Stars In Obesity Phase I

 
• By Joseph Haas

Intended as obesity monotherapy and for combination with the firm’s GLP-1 analog, MET-0233i showed best-in-class efficacy with placebo-like tolerability at low doses.